Sort   by:  
 Page size 
UnknownThe spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Deciphering Multiple Myeloma evolution in the whole bone marrow is key to inform curative strategies. Here, we perform spatial-longitudinal whole-exome sequencing, including 140 samples collected from 24 Multiple Myeloma patients during up to 14 years. Applying imaging-guided sampling we observe thr...
S-EPMC9349320 | biostudies-literature
UnknownB-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma.
Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome of 10 patients who received BCMA based therapies following ta...
S-EPMC11182413 | biostudies-literature
UnknownEpigenomic translocation of H3K4me3 broad domains over oncogenes following hijacking of super-enhancers.
Chromosomal translocations are important drivers of haematological malignancies whereby proto-oncogenes are activated by juxtaposition with enhancers, often called enhancer hijacking We analyzed the epigenomic consequences of rearrangements between the super-enhancers of the immunoglobulin he...
S-EPMC9341503 | biostudies-literature
UnknownWeight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab.
Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post-treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight du...
S-EPMC11327703 | biostudies-literature
UnknownGeographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.

Importance

The use of chimeric antigen receptor-T cell (CAR-T) therapy and bispecific antibodies in multiple myeloma is expanding, with encouraging early results. It is unknown if the current geographic distribution of CAR-T therapy and bispecific antibodies in multiple myeloma allows access...
S-EPMC9419017 | biostudies-literature
UnknownVariability of definition of high-risk multiple myeloma across phase III clinical trials.
The definition of high-risk multiple myeloma (HRMM) is evolving. Use of a clear definition of HRMM in clinical trials was not previously studied. We explored the definition of HRMM in completed phase III clinical trials. There is extreme variability in the definition and cutoffs used to define HRMM,...
S-EPMC10188470 | biostudies-literature
UnknownBone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.
Multiple myeloma (MM) patients frequently present with extensive osteolytic bone lesions. However, the impact of myeloma treatment on focal lytic lesion remineralization has not been extensively studied. In this study, the effect of anti-myeloma treatment on the extent of bone remineralization was e...
S-EPMC8627246 | biostudies-literature
UnknownLong-term outcomes after autologous stem cell transplantation for multiple myeloma.
As multiple myeloma (MM) treatments evolve, frequent updates are required to monitor the long-term effect of changes in approach. Traditionally, MM is considered an incurable disease, with most patients eventually relapsing. However, improvements in treatments has raised the possibility that MM migh...
S-EPMC6988393 | biostudies-literature
UnknownPeripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma.
Not available
S-EPMC12775428 | biostudies-literature
UnknownMesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Recent studies suggest that multiple myeloma (MM) induces proliferation and expansion of bone marrow (BM) mesenchymal stem cells (MSCs), but others showed that MM cells induce MSC senescence. To clarify the interaction between MM and MSCs, we exploited our established MSC gene signature to identify ...
S-EPMC6361704 | biostudies-literature
Sort   by:  
 Page size